Contineum Therapeutics, Inc.
CTNM$356M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO41 employees
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
CTNM News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
PIPE-791 Dose A
Idiopathic Pulmonary Fibrosis
PIPE-505
Sensorineural Hearing Loss
PIPE-307 Dose A
Relapsing Remitting Multiple Sclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PIPE-791 Dose A | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
PIPE-505 | Phase 2 | Sensorineural Hearing Loss | - | - |
PIPE-307 Dose A | Phase 2 | Relapsing Remitting Multiple Sclerosis | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply